PerkinElmer strengthens screening portfolio business
This article was originally published in Clinica
Executive Summary
Health sciences firm PerkinElmer has expanded its presence in the genetic screening market with the acquisition of the newborn metabolic screening business of Pediatrix Medical Group. The deal sees PerkinElmer gain Sunrise, Florida-based Pediatrix's StepOne newborn screening product. StepOne can analyse up to 50 inherited disorders in newborn children, claims PerkinElmer, and has been used to screen more than three million babies since Pediatrix's inception in 1994. PerkinElmer will also acquire Pediatrix's metabolic screen laboratory, which provides neonatal screening and consultancy to hospitals and medical groups, as well as the whole of Maryland, Mississippi, Louisiana, Nebraska, Pennsylvania and the District of Columbia.